Guangzhou Kaishi Pharmaceutical Co. Ltd. has patented treprostinil derivatives acting as nitric oxide (NO) donors reported to be useful for the treatment of acute respiratory distress syndrome, pulmonary arterial hypertension and arterial occlusion.
Zephyrm Biotechnologies Co. Ltd. raised ¥200 million (US$29 million) in a series B financing to support phase I and II trials of the company’s human pluripotent stem cell candidates to treat lung diseases, degenerative joint diseases such as osteoarthritis, CNS diseases, inherited retinal degenerations and retinal degenerative diseases. The money will also be used for the construction of its technology platform and cell manufacturing bases.
Zephyrm Biotechnologies Co. Ltd. raised ¥200 million (US$29 million) in a series B financing to support phase I and II trials of the company’s human pluripotent stem cell candidates to treat lung diseases, degenerative joint diseases such as osteoarthritis, CNS diseases, inherited retinal degenerations and retinal degenerative diseases. The money will also be used for the construction of its technology platform and cell manufacturing bases.
Veru Inc. announced results from an in vitro study evaluating the effects of sabizabulin against a prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells.
Tetra Bio-Pharma Inc. has received clearance from Health Canada to proceed with a first-in-human trial in Canada using oral ARDS-003 (onternabez) to treat various immunomodulatory conditions. Oral ARDS-003 is positioned to modulate acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome (ARDS) and organ damage.
Shares of Veru Inc. hit a 52-week low March 3 after the U.S. FDA declined to grant an emergency use authorization (EUA) for sabizabulin for use in hospitalized adults with moderate to severe COVID-19 who are at high risk for acute respiratory distress syndrome. The decision comes as little surprise, given the negative advisory panel vote in November, but the agency’s wording might suggest potential use for the microtubule disruptor in the future.
A new study found that nebulized mRNA therapy could be an effective approach to treating acute respiratory distress syndrome (ARDS), a rapidly progressing lung disease that can lead to respiratory failure and death. This work focused on two genes, nuclear factor kappaB (NF-κB) inhibitor α super-repressor (IκBα-SR) and superoxide dismutase 3 (SOD3), previously shown to reduce the severity of pneumonia when delivered prophylactically by viral vectors.
Chemokine-like receptor 1 (CMKLR1) is a G protein-coupled receptor for chemerin and resolvin E1 that plays a key role in the recruitment and activation of macrophages, natural killer cells and plasmacytoid dendritic cells in inflammatory diseases.
Genentech Inc. has disclosed 2,8-diazaspiro [4.5] decane compounds acting as serine/threonine-protein kinase LATS1 and/or LATS2 inhibitors reported to be useful for the treatment of acute respiratory distress syndrome (ARDS).
Tetra Bio-Pharma Inc. has reported results from a study of ARDS-003 (onternabez) combined with favipiravir against acute respiratory distress syndrome (ARDS), sepsis and COVID-19 through PREPAiRE, an artificial intelligence (AI)-powered platform which integrates target identification, validation, lead discovery optimization, drug synthesis and preclinical testing.
